These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 22921595)

  • 1. Epigenetics advancing personalized nanomedicine in cancer therapy.
    Liu S
    Adv Drug Deliv Rev; 2012 Oct; 64(13):1532-43. PubMed ID: 22921595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omics-based nanomedicine: the future of personalized oncology.
    Rosenblum D; Peer D
    Cancer Lett; 2014 Sep; 352(1):126-36. PubMed ID: 23941830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward personalized cancer nanomedicine - past, present, and future.
    Stegh AH
    Integr Biol (Camb); 2013 Jan; 5(1):48-65. PubMed ID: 22858688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetics of Early Cardiometabolic Disease: Mechanisms and Precision Medicine.
    Baccarelli AA; Ordovás J
    Circ Res; 2023 Jun; 132(12):1648-1662. PubMed ID: 37289899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics, theranostics, and personalized medicine in drug delivery systems.
    Puccetti M; Pariano M; Schoubben A; Giovagnoli S; Ricci M
    Pharmacol Res; 2024 Mar; 201():107086. PubMed ID: 38295917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanotheranostics for personalized medicine.
    Kim TH; Lee S; Chen X
    Expert Rev Mol Diagn; 2013 Apr; 13(3):257-69. PubMed ID: 23570404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promises of Nanotherapeutics in Obesity.
    Ash GI; Kim D; Choudhury M
    Trends Endocrinol Metab; 2019 Jun; 30(6):369-383. PubMed ID: 31126754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
    Gupta A; Ahmad A; Dar AI; Khan R
    Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation.
    Gonzalez-Valdivieso J; Girotti A; Schneider J; Arias FJ
    Int J Pharm; 2021 Apr; 599():120438. PubMed ID: 33662472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Epigenetics and oncology: Two faces of the personalization of medicine].
    Auroy L; Louvel S
    Med Sci (Paris); 2022 Mar; 38(3):296-302. PubMed ID: 35333168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology as a Delivery Tool for Precision Cancer Therapies.
    Sharma B; Crist RM; Adiseshaiah PP
    AAPS J; 2017 Nov; 19(6):1632-1642. PubMed ID: 29019032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoepigenetics: an element of personalized therapy?
    Majchrzak-Celińska A; Baer-Dubowska W
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):387-398. PubMed ID: 27860490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Promise of Nanotechnology in Personalized Medicine.
    Alghamdi MA; Fallica AN; Virzì N; Kesharwani P; Pittalà V; Greish K
    J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theranostic nanomedicine for cancer detection and treatment.
    Fan Z; Fu PP; Yu H; Ray PC
    J Food Drug Anal; 2014 Mar; 22(1):3-17. PubMed ID: 24673900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoepigenetics and Pharmacoepigenomics: An Overview.
    Peedicayil J
    Curr Drug Discov Technol; 2019; 16(4):392-399. PubMed ID: 29676232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker-Guided Tailored Therapy.
    Lydiard J; Nemeroff CB
    Adv Exp Med Biol; 2019; 1192():199-224. PubMed ID: 31705496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Special Issue "Recent Advances in Precision Nanomedicine for Cancer".
    Brignole C; Pastorino F
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32927825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.
    Bret C; Viziteu E; Kassambara A; Moreaux J
    Expert Rev Hematol; 2016; 9(4):351-60. PubMed ID: 26761438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer.
    Kabekkodu SP; Chakrabarty S; Ghosh S; Brand A; Satyamoorthy K
    Public Health Genomics; 2017; 20(2):100-115. PubMed ID: 28521327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.